General Court rejects Teva’s bid to overturn €60.5 million pay-for-delay fine
Drugmaker Teva and its subsidiary Cephalon have failed to quash a European Commission decision imposing €60.5 million in fines on the companies for entering into an illegal pay-for-delay agreement for a sleep disorder drug.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.